Lantheus (NASDAQ:LNTH) Downgraded to Hold Rating by Brookline Capital Markets

Brookline Capital Markets cut shares of Lantheus (NASDAQ:LNTH) from a strong-buy rating to a hold rating in a research report report published on Tuesday,Zacks.com reports.

Several other equities analysts also recently issued reports on LNTH. Weiss Ratings reissued a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research note on Wednesday. Mizuho reduced their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Wednesday. Truist Financial lifted their target price on Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Finally, Citigroup reiterated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $109.71.

Lantheus Trading Down 2.6%

Shares of NASDAQ:LNTH opened at $100.00 on Tuesday. The business’s 50-day moving average is $103.93 and its 200 day moving average is $86.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64. Lantheus has a 1 year low of $47.25 and a 1 year high of $111.86. The firm has a market capitalization of $6.51 billion, a P/E ratio of 24.10 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The company had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the business earned $1.53 EPS. Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, research analysts predict that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Hedge funds have recently bought and sold shares of the stock. Western Wealth Management LLC purchased a new position in shares of Lantheus during the 1st quarter valued at approximately $25,000. Smartleaf Asset Management LLC grew its position in Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares during the period. Parallel Advisors LLC increased its holdings in Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares in the last quarter. Osterweis Capital Management Inc. purchased a new position in Lantheus in the second quarter valued at $36,000. Finally, Bessemer Group Inc. raised its position in shares of Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 354 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.